David Patrick Ryan

David Patrick Ryan's AcademicInfluence.com Rankings

David Patrick Ryan

Philosophy

#8808

World Rank

#12260

Historical Rank

Logic

#5825

World Rank

#7265

Historical Rank

philosophy Degrees

Download Badge

Philosophy

David Patrick Ryan's Degrees

PhD Biomedical Sciences University of California, San Francisco
Doctorate Medicine Stanford University

Why Is David Patrick Ryan Influential?

(Suggest an Edit or Addition)

(See a Problem?)

David Patrick Ryan's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (2004) (1997)
NCCN Clinical Practice Guidelines in Oncology: colon cancer. (2009) (947)
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. (2012) (644)
Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. (2015) (578)
Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial. (2017) (510)
Pancreatic adenocarcinoma. (2014) (484)
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. (2006) (481)
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. (2009) (459)
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. (2005) (429)
RNA sequencing of pancreatic circulating tumour cells implicates WNT signaling in metastasis (2012) (406)
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. (2015) (396)
Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. (2006) (385)
Activity of sunitinib in patients with advanced neuroendocrine tumors. (2008) (377)
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial (2018) (371)
Pancreatic Ductal Adenocarcinoma: Is There a Survival Difference for R1 Resections Versus Locally Advanced Unresectable Tumors? What Is a “True” R0 Resection? (2013) (360)
Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. (2014) (354)
O6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors (2009) (345)
Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors (2005) (337)
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. (2017) (328)
NCCN Clinical Practice Guidelines in Oncology: rectal cancer. (2009) (324)
Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. (2016) (318)
Carcinoma of the anal canal. (2000) (299)
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. (2004) (297)
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. (2009) (293)
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. (2019) (283)
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. (2010) (272)
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers (2019) (271)
FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. (2013) (258)
Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. (2002) (247)
Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. (2015) (245)
Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma (2007) (241)
Pancreatic adenocarcinoma. (2014) (239)
Colon cancer, version 3.2014. (2014) (236)
Locally advanced pancreatic cancer. (2005) (221)
The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. (2011) (211)
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. (2011) (202)
Phase 1/2 study of everolimus in advanced hepatocellular carcinoma (2011) (187)
Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. (2005) (184)
Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. (2006) (182)
Rectal cancer, version 2.2015: Featured updates to the NCCN guidelines (2015) (167)
Unexpected Association between Induction of Immunity to the Universal Tumor Antigen CYP1B1 and Response to Next Therapy (2005) (165)
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. (2015) (163)
Molecular Alterations in Tumors and Response to Combination Chemotherapy with Gefitinib for Advanced Colorectal Cancer (2005) (162)
Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas (2006) (162)
Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. (2010) (161)
Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. (2013) (159)
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. (2007) (157)
Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach? (2012) (148)
Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer. (2015) (144)
A Phase II Study of Troglitazone, an Activator of the PPARγ Receptor, in Patients with Chemotherapy‐Resistant Metastatic Colorectal Cancer (2002) (143)
The relationship between physical and psychological symptoms and health care utilization in hospitalized patients with advanced cancer (2017) (136)
Rectal Cancer, Version 2.2015. (2015) (133)
Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. (2006) (130)
Villous Tumors of the Duodenum (1986) (127)
Coping and Prognostic Awareness in Patients With Advanced Cancer. (2017) (127)
CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma (2007) (124)
Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. (2001) (124)
An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma (2017) (119)
Lack of Efficacy of Streptozocin and Doxorubicin in Patients With Advanced Pancreatic Endocrine Tumors (2004) (115)
Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma (2014) (109)
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. (2004) (108)
Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX (2019) (108)
A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. (2014) (107)
A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. (2011) (106)
Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. (2015) (105)
Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancer. (2001) (104)
Activation of PI3K Signaling in Merkel Cell Carcinoma (2012) (103)
Quality of Life in Pancreatic Cancer: Analysis by Stage and Treatment (2008) (99)
Mutant GNAS drives pancreatic tumorigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism (2018) (97)
A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma (2002) (94)
A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma (2002) (91)
Long-term Results of Intraoperative Electron Beam Irradiation (IOERT) for Patients With Unresectable Pancreatic Cancer (2005) (91)
Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas (2004) (89)
A Phase II Trial of Irinotecan and Cisplatin in Patients with Metastatic Neuroendocrine Tumors (2006) (88)
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. (2005) (84)
Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer (2021) (81)
Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. (2012) (81)
Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma (2019) (77)
A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor (2013) (77)
Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines. (2012) (76)
Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival. (2019) (75)
Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. (2013) (73)
Localized Colon Cancer, version 3.2013 (2013) (72)
A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. (2002) (72)
A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs) (2005) (70)
Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head. (2011) (70)
Mutational analysis and clinical correlation of metastatic colorectal cancer (2014) (68)
Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET). (2017) (68)
Myeloperoxidase and superoxide dismutase polymorphisms are associated with an increased risk of developing pancreatic adenocarcinoma (2008) (67)
Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study (2013) (67)
Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastastic colorectal cancer (2007) (67)
Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. (2019) (64)
Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity (2002) (63)
Long‐term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer (2012) (63)
Adjuvant therapy for pancreatic cancer (2008) (63)
Anal carcinoma: histology, staging, epidemiology, treatment (2000) (62)
Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma (2017) (61)
Updated long‐term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010 (2013) (60)
Corrigendum: RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis (2012) (60)
A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors (2006) (60)
Tolerability of combined modality therapy for rectal cancer in elderly patients aged 75 years and older. (2011) (60)
A phase II study of sunitinib in patients with advanced hepatocellular carcinoma (2007) (59)
Phase-II Study of Gemcitabine and Cisplatin in Patients with Metastatic Biliary and Gallbladder Cancer (2008) (59)
A Phase II Study of Docetaxel in Patients with Metastatic Carcinoid Tumors (2004) (58)
A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. (2002) (58)
Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer (2014) (57)
Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma (2019) (55)
Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens (2013) (55)
Dosimetric feasibility of hypofractionated proton radiotherapy for neoadjuvant pancreatic cancer treatment. (2007) (55)
NCCN clinical practice guidelines in oncology. Anal carcinoma. (2010) (54)
Phase I Clinical Trial of STA-4783 in Combination with Paclitaxel in Patients with Refractory Solid Tumors (2007) (54)
A Phase II Trial of Irinotecan in Patients with Previously Untreated Advanced Esophageal and Gastric Adenocarcinoma (2005) (53)
Oxaliplatin-induced Evan's syndrome (2001) (52)
Anal carcinoma: Clinical practice guidelines in oncology™ (2010) (51)
Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer (2008) (51)
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors (2006) (51)
Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival (2017) (47)
Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy. (2009) (46)
Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients (2014) (46)
Pancreatic circulating tumor cell profiling identifies LIN28B as a metastasis driver and drug target (2020) (46)
Histologic and Outcome Study Supports Reclassifying Appendiceal Goblet Cell Carcinoids as Goblet Cell Adenocarcinomas, and Grading and Staging Similarly to Colonic Adenocarcinomas (2018) (46)
Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors (2005) (45)
Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers (2020) (45)
The Chicago Consensus on Peritoneal Surface Malignancies: Management of Appendiceal Neoplasms (2020) (44)
A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. (2005) (43)
A prospective feasibility study of respiratory-gated proton beam therapy for liver tumors. (2014) (42)
Toxicity and outcomes after chemoradiation for esophageal cancer in patients age 75 or older. (2009) (42)
Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study. (2008) (41)
Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529 (2017) (41)
Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. (2007) (41)
A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC). (2018) (40)
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors (2020) (38)
Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis. (2014) (38)
Adjuvant Chemotherapy for Locally Advanced Rectal Cancer: Is It a Given? (2015) (37)
Radiation Therapy Enhances Immunotherapy Response in Microsatellite-stable Colorectal and Pancreatic Adenocarcinoma in a Phase II Trial (2021) (37)
Mutational and Clinical Predictors of Pathologic Complete Response in the Treatment of Locally Advanced Rectal Cancer (2014) (36)
The role of targeted agents in preoperative chemoradiation for rectal cancer (2010) (36)
Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer. (2013) (36)
Bridge: Person-Centered Collaborative Care for Patients with Serious Mental Illness and Cancer. (2019) (36)
Clinical and treatment factors associated with vaginal stenosis after definitive chemoradiation for anal canal cancer. (2015) (36)
A Multicenter Retrospective Study on Clinical Characteristics, Treatment Patterns, and Outcome in Elderly Patients with Hepatocellular Carcinoma (2011) (36)
Tumor microenvironment immune response in pancreatic ductal adenocarcinoma patients treated with neoadjuvant therapy. (2020) (35)
Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer (2020) (35)
CORRIGENDUM: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (2004) (35)
Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment (2022) (35)
A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors. (2013) (34)
MDM2 Promoter Polymorphism and Pancreatic Cancer Risk and Prognosis (2008) (34)
Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors (2014) (34)
Inferior vena cava filter usage, complications, and retrieval rate in cancer patients. (2014) (34)
Outcomes and tolerability of chemoradiation therapy for pancreatic cancer patients aged 75 years or older. (2008) (34)
Phase I Clinical Trial of the Farnesyltransferase Inhibitor BMS-214662 Given as a 1-Hour Intravenous Infusion in Patients with Advanced Solid Tumors (2004) (33)
A Multidisciplinary Team Approach for Triage of Elective Cancer Surgery at the Massachusetts General Hospital During the Novel Coronavirus COVID-19 Outbreak (2020) (32)
Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma (2016) (32)
A Phase I Trial of Daily Oral 4′-N-Benzoyl-Staurosporine in Combination with Protracted Continuous Infusion 5-Fluorouracil in Patients with Advanced Solid Malignancies (2004) (32)
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab‐Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results (2017) (31)
Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer (2006) (31)
Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors. (2012) (30)
Functional Impairment, Symptom Burden, and Clinical Outcomes Among Hospitalized Patients With Advanced Cancer. (2020) (29)
Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody–Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies (2016) (29)
Sunitinib monotherapy in patients with advanced hepatocellular carcinoma (HCC): Insights from a multidisciplinary phase II study (2008) (29)
Single-nucleus and spatial transcriptomics of archival pancreatic cancer reveals multi-compartment reprogramming after neoadjuvant treatment (2020) (29)
Improving staging of rectal cancer in the pelvis: the role of PET/MRI (2020) (29)
Rectal cancer at the crossroads: the dilemma of clinically staged T3, N0, M0 disease. (2008) (29)
Principles of Medical Oncology and Chemotherapy (2012) (29)
Symptoms of posttraumatic stress disorder among hospitalized patients with cancer (2018) (29)
A Phase I Clinical and Pharmacokinetic Study of Oral CI-1033 in Combination with Docetaxel in Patients with Advanced Solid Tumors (2006) (28)
Predictors of Disruptions in Breast Cancer Care for Individuals with Schizophrenia. (2017) (27)
A phase II study of erlotinib in combination with capecitabine in previously treated patients with metastatic pancreatic cancer (2005) (27)
A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma (mCRC). (2019) (27)
Exploratory Analysis of Early Toxicity of Sunitinib in Advanced Hepatocellular Carcinoma Patients: Kinetics and Potential Biomarker Value (2010) (27)
Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer. (2014) (26)
Predictors of Posthospital Transitions of Care in Patients With Advanced Cancer. (2018) (26)
A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors. (2002) (26)
A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors (2000) (26)
Clinical Practice Guidelines in Oncology TM (2009) (26)
Cost-effectiveness of Short-Course Radiation Therapy vs Long-Course Chemoradiation for Locally Advanced Rectal Cancer (2019) (26)
Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy. (2012) (25)
Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis (2009) (25)
Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer. (2008) (25)
SO-26 Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients (2020) (24)
Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer (2021) (23)
Reality testing in cancer treatment: the phase I trial of endostatin. (2002) (23)
Phase I and Pharmacokinetic Study of Gimatecan Given Orally Once a Week for 3 of 4 Weeks in Patients with Advanced Solid Tumors (2009) (22)
Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer-The New Standard of Care? (2018) (22)
T3N0 rectal cancer: radiation for all? (2011) (22)
Symptom burden in patients with cancer who are experiencing unplanned hospitalization (2020) (22)
Pilot randomized trial of an electronic symptom monitoring intervention for hospitalized patients with cancer (2019) (22)
Clinical impact of PET/MR in treated colorectal cancer patients (2019) (22)
Improved Detection of Circulating Epithelial Cells in Patients with Intraductal Papillary Mucinous Neoplasms (2017) (21)
Safety and effectiveness of oxaliplatin-based chemotherapy regimens in adults 75 years and older with colorectal cancer. (2013) (21)
Association Between Very Small Tumor Size and Increased Cancer-Specific Mortality in Node-Positive Colon Cancer (2016) (21)
Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study (2013) (21)
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer (2007) (21)
Dose--volume effects on patient-reported acute gastrointestinal symptoms during chemoradiation therapy for rectal cancer. (2012) (21)
Colon Cancer , Version 3 . 2014 Clinical Practice Guidelines in Oncology (2014) (21)
Processes of code status transitions in hospitalized patients with advanced cancer (2017) (20)
The Chicago Consensus on peritoneal surface malignancies: Management of appendiceal neoplasms (2020) (20)
Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma (2019) (20)
Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer. (2004) (20)
Neoadjuvant Chemotherapy for Gastric Cancer: What are we Trying to Accomplish? (2013) (20)
Phase I study of DKN-01, an anti-DKK1 antibody, in combination with paclitaxel (pac) in patients (pts) with DKK1+ relapsed or refractory esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ). (2016) (19)
Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer. (2014) (19)
Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma. (2020) (19)
Phase I trial of ARQ 501, an Activated Checkpoint Therapy (ACT) agent, in patients with advanced solid tumors (2005) (19)
Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations (2021) (18)
Phase 1 study of N1,N11-diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma (2013) (18)
Pilot randomized trial of an electronic symptom monitoring intervention for hospitalized patients with cancer. (2019) (17)
Impact of adjuvant therapy in patients with invasive intraductal papillary mucinous neoplasms of the pancreas. (2020) (17)
Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours. (2006) (17)
Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. (2006) (17)
BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212). (2012) (16)
American Society of Clinical Oncology 2010 colorectal update (2010) (16)
Integrated, Multidisciplinary Management of Pulmonary Nodules Can Streamline Care and Improve Adherence to Recommendations. (2019) (16)
TGF-B1 inhibition with losartan in combination with FOLFIRINOX (F-NOX) in locally advanced pancreatic cancer (LAPC): Preliminary feasibility and R0 resection rates from a prospective phase II study. (2017) (16)
A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression. (2014) (16)
Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis (2018) (16)
Phase I study of neoadjuvant bevacizumab, 5-fluorouracil, and radiation therapy followed by surgery for patients with primary rectal cancer (2004) (16)
Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting. (2020) (15)
Pilot Randomized Trial of a Pharmacy Intervention for Older Adults with Cancer. (2018) (15)
Abstract LB-121: Randomized phase II study of the efficacy and safety of gemcitabine + TH-302 (G+T) vs gemcitabine (G) alone in previously untreated patients with advanced pancreatic cancer (2012) (15)
Patients Undergoing Treatment for Pancreatic Adenocarcinoma Can Mount an Effective Immune Response to Vaccinations (2005) (15)
Phase I/II study of everolimus in patients with advanced hepatocellular carcinoma (HCC). (2010) (14)
The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2012 (2013) (14)
Sexual Function, Quality of Life, and Mood After Radiation Therapy in Patients with Anal Cancer (2019) (14)
Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases (2017) (14)
Radiomics Texture Features in Advanced Colorectal Cancer: Correlation with BRAF Mutation and 5-year Overall Survival. (2020) (14)
Pharmacodynamic and efficacy analysis of the BRAF inhibitor dabrafenib (GSK436) in combination with the MEK inhibitor trametinib (GSK212) in patients with BRAFV600 mutant colorectal cancer (CRC). (2013) (13)
Controversy and Consensus on the Management of Patients With Pseudomyxoma Peritonei (2013) (13)
Irradiation of anatomically defined pelvic subsites and acute hematologic toxicity in anal cancer patients undergoing chemoradiation. (2017) (13)
The Combination of Capecitabine and Thalidomide in Previously Treated, Refractory Metastatic Colorectal Cancer (2006) (13)
Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer (2018) (13)
Pencil Beam Scanning Proton Beam Chemoradiotherapy with 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study. (2019) (13)
Phase II Study of the Antiangiogenic Agent SU 5416 in Patients with Advanced Soft Tissue Sarcomas (2004) (13)
A phase II study of gemcitabine, oxaliplatin in combination with bevacizumab (GEMOX-B) in patients with hepatocellular carcinoma (2005) (13)
Current perspectives on anal cancer. (2003) (12)
HIPEC for colorectal peritoneal metastases. (2021) (12)
A phase I/II study of bevacizumab (beva), erlotinib (erl), and 5-fluorouracil (5-FU) with concurrent external beam radiation therapy (RT) in locally advanced rectal cancer (LARC). (2016) (12)
Predictors of Early Mortality After Surgical Resection of Pancreatic Adenocarcinoma in the Era of Neoadjuvant Treatment (2017) (12)
Mitomycin in anal cancer: still the standard of care. (2012) (12)
High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy (2019) (12)
Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis (2017) (12)
Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis. (2018) (12)
Enrichment of HER2 Amplification in Brain Metastases from Primary Gastrointestinal Malignancies. (2018) (12)
Management of locally advanced adenocarcinoma of the pancreas. (2002) (12)
Activation of PI 3 K Signaling in Merkel Cell Carcinoma (2012) (11)
Long-term results of intraoperative electron beam irradiation for patients with unresectable pancreatic cancer (2003) (11)
Prediction of response to temozolomide (TMZ)-based therapy by loss of MGMT expression in patients with advanced neuroendocrine tumors (NET) (2007) (11)
A critical look at local-regional management of peritoneal metastasis. (2015) (11)
A Phase I study of 9‐nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors (2003) (11)
A phase II study of docetaxel in combination with ZD1839 (gefitinib) in previously treated patients with metastatic pancreatic cancer (2007) (11)
A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer (2020) (11)
Updated results of a phase I study of pasireotide (SOM230) in combination with everolimus (RAD001) in patients (pts) with advanced neuroendocrine tumors (NET). (2011) (11)
Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer. (2006) (11)
Phase II study of cetuximab in patients with unresectable or metastatic hepatocellular carcinoma. (2006) (10)
Standard fractionation external beam radiotherapy with and without intraoperative radiotherapy for locally recurrent rectal cancer: the role of local therapy in patients with a high competing risk of death from distant disease. (2017) (10)
A phase II study of ipilimumab and nivolumab with radiation in metastatic pancreatic adenocarcinoma. (2019) (10)
Phase II study of RAD001 in previously treated patients with metastatic pancreatic cancer (2008) (10)
Potentially curative combination of TGF-b1 inhibitor losartan and FOLFIRINOX (FFX) for locally advanced pancreatic cancer (LAPC): R0 resection rates and preliminary survival data from a prospective phase II study. (2018) (10)
MLN0264, an investigational antiguanylyl cyclase C (GCC) antibody-drug conjugate (ADC), in patients (pts) with advanced gastrointestinal (GI) malignancies: Phase I study. (2014) (10)
Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC). (2004) (10)
Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes. (2021) (10)
FOLFIRINOX in locally advanced or metastatic pancreatic cancer. (2012) (10)
Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors. (2003) (9)
Phase II study of docetaxel, cisplatin, and irinotecan in advanced esophageal and gastric cancer. (2004) (9)
Combined Modality Therapy for Rectal Cancer. (2016) (9)
A phase I/II study of preoperative oxaliplatin (O), 5-fluorouracil (5-FU), and external beam radiation therapy (XRT) in locally advanced rectal cancer: CALGB 89901. (2004) (9)
Chemoradiation-related lymphopenia and its association with survival in patients with squamous cell carcinoma of the anal canal. (2020) (8)
Reverse Transcriptase Inhibition Disrupts Repeat Element Life Cycle in Colorectal Cancer. (2022) (8)
Using circulating tumor DNA (ctDNA) to predict surgical outcome after neoadjuvant chemoradiation for locally advanced pancreatic cancer (LAPC). (2018) (8)
Abstract LB-302: Potent antitumor activity of XL184 (cabozantinib), a c-MET and VEGFR2 inhibitor, in colorectal cancer patient-derived tumor explant models. (2013) (8)
P-348 A phase I trial of gemcitabine followed by flavopiridol in patients with solid tumors (2003) (8)
A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer (2020) (8)
Early integrated palliative care to improve family caregivers (FC) outcomes for patients with gastrointestinal and lung cancer. (2016) (8)
Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study (2021) (8)
Pancreatic Cancer: A Time to Change. (2020) (8)
Use of Antidepressant Medications Moderates the Relationship Between Depressive Symptoms and Hospital Length of Stay in Patients with Advanced Cancer (2018) (8)
Precision medicine in pancreatic cancer: Patient derived organoid pharmacotyping is a predictive biomarker of clinical treatment response. (2022) (7)
Chemotherapy Errors: A Call for a Standardized Approach to Measurement and Reporting. (2016) (7)
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: Phase 1 results. (2015) (7)
Phase II study of FOLFOX, bevacizumab and erlotinib as initial therapy for patients with metastatic colorectal cancer (MCRC). (2006) (7)
Clinical, pharmacodynamic (PD), and pharmacokinetic (PK) evaluation of cediranib in advanced hepatocellular carcinoma (HCC): A phase II study (CTEP 7147). (2012) (7)
Temporal Trends in Inpatient Oncology Census Before and During the COVID‐19 Pandemic and Rates of Nosocomial COVID‐19 Among Patients with Cancer at a Large Academic Center (2021) (7)
750PPhase Ib study of PF-04136309 (an oral CCR2 inhibitor) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic adenocarcinoma (2017) (7)
Capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer (2004) (7)
TH-302 plus gemcitabine (G+T) versus gemcitabine (G) in patients with previously untreated advanced pancreatic cancer (PAC). (2013) (7)
Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer? (2015) (7)
Randomized phase II study of the efficacy and safety of gemcitabine plus TH-302 versus gemcitabine alone in previously untreated patients with advanced pancreatic cancer. (2011) (6)
Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors (2006) (6)
Effect of early integrated palliative care on family caregivers (FC) outcomes for patients with gastrointestinal and lung cancer. (2016) (6)
A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer (2012) (6)
Systematic liquid biopsy identifies novel and heterogeneous mechanisms of acquired resistance in gastrointestinal (GI) cancer patients. (2017) (6)
A Phase II Study of Modified deGramont 5-Fluorouracil, Leucovorin, and Oxaliplatin in Previously Treated Patients with Metastatic Colorectal Cancer (2003) (6)
Novel use of proton beam therapy for neoadjuvant treatment of radiation-associated squamous cell carcinoma of the esophagus. (2018) (6)
A multi-institutional phase II open-label study of AMG 479 in advanced carcinoid and pancreatic neuroendocrine tumors. (2012) (6)
A phase I dose-finding study of sunitinib (SU) in combination with gemcitabine (G) in patients (pts) with advanced solid tumors (2008) (6)
Necuparanib combined with nab-paclitaxel + gemcitabine in patients with metastatic pancreatic cancer: Phase 2 results. (2017) (6)
Phase I dose‐escalation study of tezacitabine in combination with 5‐fluorouracil in patients with advanced solid tumors (2005) (6)
Emerging therapies for colorectal cancer (2007) (6)
Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism (2018) (6)
Gastrointestinal tumors, non-colorectal (2012) (6)
A phase 1, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 x CD3 DART molecule, in patients with relapsed/refractory metastatic colorectal carcinoma. (2016) (6)
Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy (2021) (5)
Associations of baseline patient‐reported outcomes with treatment outcomes in advanced gastrointestinal cancer (2020) (5)
Clinical staging in pancreatic adenocarcinoma underestimates extent of disease. (2020) (5)
Treatment of peritoneal carcinomatosis of colorectal origin. (2015) (5)
Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control. (2014) (5)
Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma (2020) (5)
Effect of a Symptom Monitoring Intervention for Patients Hospitalized With Advanced Cancer: A Randomized Clinical Trial. (2022) (5)
Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor , BAY 43-9006 , in Patients with Advanced , Refractory SolidTumors (2005) (5)
A pilot study of durvalumab/tremelimumab (durva/treme) and radiation (XRT) for metastatic biliary tract cancer (mBTC): Preliminary safety and efficacy. (2020) (5)
A pilot feasibility study of definitive concurrent chemoradiation with pencil beam scanning proton beam in combination with 5-fluorouracil and mitomycin-c for carcinoma of the anal canal. (2018) (5)
A phase II clinical trial of ganetespib (STA-9090) in previously treated patients with advanced esophagogastric cancers. (2013) (5)
Phase II study of autophagy inhibition with hydroxychloroquine (HCQ) and preoperative (preop) short course chemoradiation (SCRT) followed by early surgery for resectable ductal adenocarcinoma of the head of pancreas (PDAC). (2017) (5)
The Impact of Positive Margins on Outcome Among Patients With Gastric Cancer Treated With Radiation (2016) (5)
A pilot study of neoadjuvant FOLFIRINOX followed by chemoradiation for gastric and gastroesophageal cancer: Preliminary results. (2019) (4)
Trees, forests, and other implications of a BRAF mutant gene signature in patients with BRAF wild-type disease. (2012) (4)
Predicting a response to FOLFIRINOX in pancreatic cancer. (2015) (4)
A single-arm trial of panitumumab in cetuximab refractory KRAS wild-type colorectal cancer. (2011) (4)
Symptom burden in hospitalized patients with advanced cancer. (2015) (4)
Phase Ib study of neoadjuvant chemoradiation (CRT) with midostaurin, 5-fluorouracil (5-FU) and radiation (XRT) for locally advanced rectal cancer: Sensitization of RAS mutant tumors. (2018) (4)
PD-016Current results of a phase I study of DKN-01 in combination with paclitaxel (P) in patients (pts) with advanced DKK1+ esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ) (2016) (4)
Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas (2020) (4)
Multidisciplinary management of early-stage rectal cancer. (2012) (4)
Phase I Study of Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer (2012) (4)
PD-0032MLN0264, AN INVESTIGATIONAL, FIRST-IN-CLASS ANTIBODY-DRUG CONJUGATE TARGETING GUANYLYL CYCLASE C (GCC): FIRST-IN-HUMAN STUDY IN PATIENTS WITH ADVANCED GASTROINTESTINAL MALIGNANCIES (2013) (4)
Caring for one of our own. (2014) (4)
Dose intensity of neoadjuvant FOLFIRINOX (FFX) in borderline and locally advanced pancreatic cancer (LAPC): A comparison to the adjuvant benchmark. (2019) (4)
Case 20-2005: A 58-Year-Old Man with Locally Advanced Pancreatic Cancer (2005) (4)
Improving safety culture at a large AMC. (2014) (4)
A phase I study of temsirolimus in combination with gemcitabine in previously untreated metastatic pancreatic cancer. (2012) (4)
Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial (2023) (4)
Phase I study of neoadjuvant bevacizumab, 5-fluorouracil, and radiation therapy followed by surgery for patients with primary rectal cancer. (2004) (4)
Supportive Oncology Care at Home Intervention for Patients With Pancreatic Cancer (2021) (4)
Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation (2020) (4)
Understanding the Paradigm Shift in Pancreatic Cancer. (2016) (4)
The Art of Oncology: COVID‐19 Era (2020) (4)
Care Patterns and Overall Survival in Patients With Early-Onset Metastatic Colorectal Cancer. (2021) (4)
Nonsurgical approaches to colorectal cancer. (2006) (4)
Novel therapies in colon cancer (2006) (4)
Severe immune-related adverse effects (irAE) requiring hospital admission in patients treated with immune checkpoint inhibitors for advanced malignancy: Temporal trends and clinical significance. (2018) (4)
Validation of the NSABP neoadjuvant rectal score (NAR) in a prospective phase II study evaluating an experimental regimen and a standard chemoradiation cohort with molecular genotyping. (2014) (4)
A phase 1 study of TAK-164, an anti-guanylyl cyclase C (GCC) antibody-drug conjugate (ADC), in patients (pts) with advanced gastrointestinal (GI) cancers expressing GCC. (2021) (3)
Pilot of Respiratory Gated Proton Beam Therapy for Liver Tumors (2009) (3)
Outcomes following liver SBRT for metastatic pancreatic cancer. (2019) (3)
Using circulating tumor DNA (ctDNA) to predict surgical outcome and postoperative recurrence following neoadjuvant chemoradiation (CRT) for borderline resectable/locally advanced rectal cancer (LARC). (2019) (3)
Characterization of unplanned 30-day medical oncology readmissions after discharge at an academic medical center with a comprehensive cancer center. (2016) (3)
Phase II study of lamivudine in p53 mutant metastatic colorectal cancer (mCRC). (2020) (3)
P-0173PHASE 3 TRIAL OF GEMCITABINE AND TH-302 COMPARED WITH GEMCITABINE AND PLACEBO IN PATIENTS WITH PANCREATIC ADENOCARCINOMA: THE MAESTRO TRIAL (2013) (3)
Rectal cancer: integrating oxaliplatin into chemoradiation studies. (2000) (3)
Relationship of EGFR-independent activation of PI3K in KRAS wild-type colorectal cancers and cetuximab resistance. (2013) (3)
PARP-ness in metastatic colorectal cancer. (2019) (3)
Detection of liver metastases from gastrointestinal cancer: comparision of high resolution MnDPDP enhanced MRI and FDG-PET. (2005) (3)
Phase 1 Dose-Escalation Trial of the Investigational Hedgehog (HH) Pathway Inhibitor Tak-441 in Patients with Advanced Solid Tumors (2012) (3)
Multicenter randomized phase II trial of cisplatin, irinotecan plus bevacizumab (PCA) versus docetaxel, cisplatin, irinotecan plus bevacizumab (TPCA) in patients (pts) with metastatic esophagogastric cancer (MEGCA). (2012) (3)
Inflammatory Signaling and Fibroblast-Cancer Cell Interactions Transfer from a Harmonized Human Single-cell RNA Sequencing Atlas of Pancreatic Ductal Adenocarcinoma to Organoid Co-Culture (2022) (3)
Addition of losartan to FOLFORINOX and chemoradiation downregulates pro-invasion and immunosuppression-associated genes in locally advanced pancreatic cancer (2022) (3)
Gemcitabine (G) + nab-paclitaxel (nab-P) versus G in patients (pts) with advanced pancreatic cancer (PDAC) after FOLFIRINOX: A single center, retrospective review. (2016) (3)
Proof of concept of the abscopal effect in MSS GI cancers: A phase 2 study of ipilimumab and nivolumab with radiation in metastatic pancreatic and colorectal adenocarcinoma. (2019) (2)
Long-term Outcomes of Neoadjuvant Chemotherapy (NC) before Chemoradiation (CRT) for Locally Advanced Pancreatic Cancer (LAPC) (2011) (2)
Phase I Clinical Trial and Pharmacokinetic Study of the Spicamycin Analog KRN 5500 Administered as a 1-Hour Intravenous Infusion for Five Consecutive Days to Patients with Refractory Solid Tumors (2003) (2)
Efficacy, safety, and changes in blood markers following sunitinib monotherapy in patients with advanced hepatocellular carcinoma: Experience from a multidisciplinary Phase II study (2008) (2)
Mutational analysis and clinical correlation of 185 consecutive metastatic colorectal patients: Similarities and differences between colon and rectal patients. (2011) (2)
Author Correction: Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers (2019) (2)
Effect of molecular genotyping to predict outcomes in patients with metastatic pancreatic cancer. (2014) (2)
The effect and mechanism of M402 on gemcitabine uptake into pancreatic tumors. (2014) (2)
Modeling and improving chemotherapy patient flow. (2014) (2)
Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case report. (2021) (2)
Phase I/II study of Proton-based Short Course Chemoradiation and Early Surgery for Adenocarcinoma of the Pancreas (2010) (2)
Multi-institutional phase II study of high dose, hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers: Long term outcomes in patients (pts) with intrahepatic cholangiocarcinoma (ICC). (2015) (2)
Symptom burden in hospitalized patients with curable and incurable cancers. (2018) (2)
The use of elevated circulating hepatocyte growth factor (HGF) level as a potential prognostic biomarker in locally advanced pancreatic cancer. (2021) (2)
Long Term Follow-up of a Phase II Study of Autophagy Inhibition with Hydroxychloroquine (HCQ) and Preoperative (Preop) Short Course Chemoradiation (SCRT) Followed by Early Surgery for Resectable Ductal Adenocarcinoma of the Head of Pancreas (PDAC) (2020) (2)
A phase I study of E7070, a chloroindolyl-sulfonamide, in combination with irinotecan in gastrointestinal and thoracic carcinomas (2005) (2)
Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy (2021) (2)
Enhancement of anti-tumor immunity and survival prolongation by neoadjuvant 5-FU, oxaliplatin and irinotecan (folfirinox) in pancreatic ductal adenocarcinoma patients (2018) (2)
MLN0264, an investigational, first-in-class antibody-drug conjugate (ADC) targeting guanylyl cyclase C (GCC): Phase I, first-in-human study in patients (pts) with advanced gastrointestinal (GI) malignancies expressing GCC. (2013) (2)
Phase I and Pharmacokinetic Study of Ecteinascidin 743 Administered as a 72-Hour Continuous Intravenous Infusion in Patients with Solid Malignancies 1 (2001) (2)
A Pilot Study of Neoadjuvant FOLFIRINOX followed by Chemoradiation for Gastric and Gastroesophageal Cancer: Preliminary Results and Prognostic Implications of ctDNA (2019) (2)
Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) Versus the Standard of Care Imaging in the Diagnosis of Peritoneal Carcinomatosis (2022) (2)
Phase I/II study of preoperative (pre-op) short course chemoradiation (CRT) with proton beam therapy (PBT) and capecitabine (cape) followed by early surgery for resectable pancreatic ductal adenocarcinoma (PDAC) of the head. (2012) (2)
Immediate versus delayed adjuvant chemoradiation for resected pancreatic cancer: An analysis of local control and survival. (2012) (2)
Relationship of incomplete inhibition of PI3K pathway signaling and efficacy of cetuximab in KRAS wild-type colorectal cancers. (2012) (2)
Phase I dose escalation study of a polymeric micellar formulation of paclitaxel in patients (pts) with refractory non-hematologic cancer (2005) (2)
Current results of a phase I study of DKN-01, an anti-DKK1 antibody, in combination with paclitaxel (P) in patients (pts) with advanced DKK1+ esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ). (2016) (2)
Circulating biomarkers in a phase II study of hypofractionated proton beam therapy (H-PBT) for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). (2016) (1)
Clinical correlation with codon-specific mutations in metastatic colorectal cancer. (2016) (1)
Preliminary analysis of total neoadjuvant therapy for patients with locally advanced gastric (G) and gastroesophageal (GE) adenocarcinoma. (2020) (1)
Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors (2015) (1)
Phase I trials with ET-743, a marine derived (MD) anticancer agent (1999) (1)
Pancreatic Neuroendocrine Tumors With Involved Surgical Margins: Prognostic Factors and the Role of Adjuvant (2012) (1)
O-0008 Phase II Study of Gemcitabine + TH-302 vs Gemcitabine Alone in Patients with Locally Advanced and Metastatic Pancreatic Cancer (2012) (1)
Improved Detection of Circulating Epithelial Cells in Patients with Intraductal Papillary Mucinous Neoplasms (2018) (1)
Frequency and impact of tumor genotyping in clinical practice of patients with advanced biliary tract cancers (ABTCs). (2017) (1)
Safety and Feasibility of Same-session Endoscopic Ultrasound-guided Biopsy and Fiducial Placement in Pancreatic Cancer (2021) (1)
Neoadjuvant versus Postoperative Chemoradiotherapy is Associated with Improved Survival for Patients with Resectable Gastric and Gastroesophageal Cancer (2021) (1)
A Single Arm Phase 2 Study of Individualized Proton-Based Stereotactic Body Radiation Therapy (P-SBRT) of Liver Metastases (2015) (1)
Radiation recall associated with insulin growth factor 1R antibody. (2011) (1)
Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Non-Metastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis. (2022) (1)
Noninvasive comprehensive genomic profiling from plasma ctDNA in pancreatic cancer patients. (2020) (1)
Clinical and Molecular Predictors of Local Failure After SBRT for Liver Metastases: A Secondary Analysis of a Prospective Phase II Trial (2015) (1)
O-0009PHASE I STUDY OF THE INVESTIGATIONAL ANTI-GUANYLYL CYCLASE C (GCC) ANTIBODY-DRUG CONJUGATE (ADC) MLN0264 IN ADULT PATIENTS WITH ADVANCED GASTROINTESTINAL MALIGNANCIES EXPRESSING GCC (2014) (1)
Efficacy and safety of gemcitabine in combination with TH-302 compared with gemcitabine in combination with placebo in previously untreated patients with metastatic or locally advanced unresectable pancreatic adenocarcinoma: The MAESTRO trial. (2013) (1)
FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer: Preliminary toxicity and R0 resection rates from a prospective phase II study. (2017) (1)
Capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. (2004) (1)
Clinical outcomes of patients with stage IV cancer receiving immune checkpoint inhibitors in the inpatient setting. (2019) (1)
Study protocol for a randomized trial of bridge: Person-centered collaborative care for serious mental illness and cancer. (2022) (1)
FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer (BRPC): Toxicity, R0 resection, and interim survival data from a prospective phase II study. (2017) (1)
218 A phase I and pharmacokinetic trial ARQ 501, an Activated Checkpoint Therapy (TM) agent, in patients with advanced solid tumors (2004) (1)
Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers. (2020) (1)
Pancreatoblastoma in a teenage patient. (2006) (1)
Total Neoadjuvant TherapyWith FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma A Phase 2 Clinical Trial (2018) (1)
Intraoperative radiotherapy (IORT) in the era of intensive neoadjuvant chemotherapy and chemoradiotherapy for locally advanced and borderline resectable adenocarcinoma of the pancreas (PDAC). (2016) (1)
HER2 positivity in brain metastases from gastrointestinal primary malignancies. (2018) (1)
To HIPEC or Not to HIPEC? That Is The Question (2014) (1)
Efficacy, safety, and changes in angiogenic markers following sunitinib monotherapy in patients with advanced hepatocellular carcinoma: Experience from a phase II study. (2007) (1)
Analysis of DNA damage response (DDR) genes and tumor mutational burden (TMB) across 17,486 carcinomas of the tubular GI tract: Implications for therapy. (2018) (1)
Serial circulating tumor DNA (ctDNA) monitoring to predict response to treatment in metastatic gastrointestinal cancers. (2019) (1)
A phase II study of gemcitabine (G), bevacizumab (B), and erlotinib (E) in locally advanced (LAPC) and metastatic adenocarcinoma (MPC) of the pancreas (2008) (1)
Functional SNPs in vascular endothelial growth factor (VEGF-A) and overall survival (OS) in bevacizumab-treated patients with metastatic colorectal cancer (mCRC). (2012) (1)
Potentially avoidable hospitalizations in patients with advanced cancer. (2017) (1)
Phase I study of preoperative (pre-op) short course chemoradiation (CRT) with proton beam therapy (PBT) and capecitabine (cape) for resectable pancreatic ductal adenocarcinoma (PDAC) of the head. (2009) (1)
Influence of Body Mass Index (BMI) on Colorectal Cancer Mutation Status (2015) (1)
Case records of the Massachusetts General Hospital. Case 19-2010. A 35-year-old man with adenocarcinoma of the cecum. (2010) (1)
Intraductal papillary mucinous adenocarcinoma of the pancreas: clinical outcomes, prognostic factors, and the role of adjuvant therapy. (2011) (1)
Evolutionary Analysis of Pre- and Post-treatment Molecular Diversity in Rectal Cancer Patients Receiving Neoadjuvant Chemoradiation (CRT) and a KRAS Mutation-targeted Radiosensitizer (2020) (1)
STA-4783 in combination with paclitaxel induces heat shock protein 70 (hsp70) in a phase I trial (2005) (1)
Abstract C043: Addition of losartan to FOLFORINOX and chemoradiation downregulates pro-invasion and immunosuppression-associated genes in locally advanced pancreatic cancer (2022) (1)
The Increasingly Complicated Approach to Rectal Cancer. (2019) (1)
Symptom burden to predict health care utilization in hospitalized patients with incurable cancer. (2016) (1)
Quantitative MR imaging biomarkers of tumor heterogeneity predict prognosis in metastatic colorectal lesions. (2017) (1)
A multicenter, randomized phase II study of total neoadjuvant therapy (TNT) with FOLFIRINOX (FFX) and SBRT, with or without losartan (L) and nivolumab (N) in borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC). (2023) (1)
The wide gulf between stage III and stage IV colon cancer. (2014) (1)
Abstract A34: Hypoxia-activated prodrug TH-302 in combination with gemcitabine for the treatment of pancreatic adenocarcinoma: Preclinical and clinical studies. (2012) (1)
CMET-33. PHASE II STUDY OF PALBOCICLIB IN BRAIN METASTASES HARBORING CDK PATHWAY ALTERATIONS (2019) (0)
Evaluating the Impact of Combination of Nivolumab and Ipilimumab to Liver/Lung SBRT on Local Control for Colorectal and Pancreatic Cancer: A Pooled Analysis of Two Prospective Trials (2019) (0)
Improved Outcomes of Invasive Papillary Mucinous Tumors of the Pancreas, Different Biology or Different Stage? (2007) (0)
A Pilot Feasibility Study of Definitive Concurrent Chemoradiation with Pencil Beam Scanning Proton Beam in Combination with 5-fluorouracil and Mitomycin-c for Carcinoma of the Anal Canal (2018) (0)
A phase I study of DENSPM (N1, N11-diethylnorspermine) in patients with advanced hepatocellular carcinoma (HCC). (2013) (0)
Clinical and Treatment Factors Associated With Vaginal Stenosis After Definitive Chemoradiation for Anal Cancer (2013) (0)
Gastric adenocarcinoma treated with radiation with or without epirubicin-based chemotherapy: Evaluation of radiation-induced liver disease. (2011) (0)
Patient-reported care satisfaction and symptom burden in hospitalized patients with cancer. (2020) (0)
Mutational analysis of locally advanced rectal cancer and response to neoadjuvant chemoradiation. (2013) (0)
Clinical and mutational profile of ARID1A-mutated gastrointestinal cancers: Duration of response to platinum-based chemotherapy. (2021) (0)
APhase I Clinical and Pharmacokinetic Study of Oral CI-1033 in Combinationwith Docetaxel in Patients with Advanced Solid Tumors (2006) (0)
The importance of recognizing and addressing depression in patients with advanced cancer. (2017) (0)
Abstract C012: Dissecting the reorganization of pancreatic tumor microenvironments after radiation and immunotherapy reveals insights into immunotherapy resistance (2022) (0)
Cost-effectiveness of short course radiation therapy versus long-course chemoradiation for locally advanced rectal adenocarcinoma. (2018) (0)
Phase I ClinicalTrial of STA-4783 in Combinationwith Paclitaxel in Patients with Refractory SolidTumors (2007) (0)
Patient-reported outcomes: Completion, access, and equity. (2022) (0)
MET-amplification (MET-amp) in relation to aggressive biology in esophagogastric cancer (EGC): An analysis of clinical outcomes of MET-amp vs non-MET-amp EGC. (2018) (0)
The integration of biologic agents into the current systemic management of rectal cancer (2005) (0)
Continuing Progress in the Interdisciplinary Management of Peritoneal Metastases (2022) (0)
Efﬁcacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study (2009) (0)
Genetic, tissue, and plasma biomarkers of outcomes from a prospective study of neoadjuvant short course proton-based chemoradiation for resectable pancreatic ductal adenocarcinoma (PDAC). (2013) (0)
Post-discharge transitions of care for hospitalized patients with advanced cancer. (2017) (0)
A Phase I Clinical Trial of Sequentially Administered Doxorubicin and Topotecan in Refractory Solid Tumors 1 (2002) (0)
Erratum: Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma (Proceedings of the National Academy of Sciences of the United States of America (2019) 116 (26835–26845) DOI: 10.1073/pnas.1914915116) (2020) (0)
Intraoperative Radiation Therapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiation Therapy for Pancreatic Adenocarcinoma (2016) (0)
1463 Addition of losartan to FOLFORINOX and chemoradiation downregulates pro-invasion and immunosuppression associated genes in locally advanced pancreatic cancer (2022) (0)
Radiation Induced Checkpoint Immunotherapy Response in Refractory Colorectal and Pancreatic Adenocarcinoma (2020) (0)
Randomized trial of a symptom monitoring intervention for hospitalized patients with cancer. (2018) (0)
Long Term Risk of Pelvic Insufficiency Fractures and Lower Extremity Edema After Definitive Chemoradiation for Squamous Cell Carcinoma of the Anal Canal. (2021) (0)
Circulating oncometabolite 2-hydroxyglutarate (2HG) as a potential surrogate biomarker in patients with isocitrate dehydrogenase mutant (IDHm) intrahepatic cholangiocarcinoma (ICC). (2013) (0)
Preoperative chemoradiotherapy versus postoperative chemoradiotherapy for local advanced gastric or Siewert II/III GEJ cancer: A retrospective analysis. (2018) (0)
Pancreatic circulating tumor cell profiling identifies LIN28B as a metastasis driver and drug target (2020) (0)
ADJUVANT CHEMORADIATION PROVIDES BENEFIT FOR PATIENTS WITH ADVANCED INVASIVE INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM (2007) (0)
IS-10-1 Predictors of lymph node involvement in T1 gastric carcinoma(IS-10 International Session (10) Upper gastrointestinal tract surgery) (2014) (0)
DNA mutation frequencies in metastatic small bowel adenocarcinoma (mSBA) in comparison to gastric (mGC), colon (mCC), and rectal cancer (mRC): Continuum or cutpoint? (2013) (0)
Cost-Effectiveness of Short Course Radiation Therapy Versus Long-Course Chemoradiation for Locally Advanced Rectal Adenocarcinoma (2018) (0)
Early toxicity of sunitinib as a potential predictive biomarker in advanced hepatocellular carcinoma (HCC) patients. (2010) (0)
A systematic liquid biopsy program identifies novel and heterogeneous mechanisms of acquired resistance in gastrointestinal (GI) cancer patients (2016) (0)
Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer A C (2021) (0)
Author Correction: Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers (2019) (0)
The Immune Milieu of Anal Squamous Cell Carcinoma: IDO Expression is Correlated with Poor Outcome (2018) (0)
High Baseline TNF-α Levels may Associate with Poor Outcomes after Total Neoadjuvant Therapy for Gastroesophageal Cancer: Initial Biomarker Analysis from a Prospective Study (2022) (0)
Abstract LB-257: Liquid biopsy versus tissue biopsy to assess acquired resistance and tumor heterogeneity in gastrointestinal cancers (2019) (0)
Background M402, a Novel Drug Candidate for Pancreatic Cancer: Efficacy in Animal Models and Initial Clinical Study Design (2014) (0)
Rectal Cancer (2018) (0)
Patient Tolerability and Acute Toxicity of Intensity Modulated Radiation Therapy for Treatment of Carcinomas of the Biliary Tract (2011) (0)
Long-term Outcomes and Prognostic Factors for Locally-Advanced Pancreatic Cancer Patients Treated With Intraoperative Radiation Therapy (2013) (0)
Clinical Predictors and Outcomes of Superior Mesenteric Vein or Portal Vein Thrombosis in the Setting of Neoadjuvant Therapy for Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma (2015) (0)
Abstract 1734: Absolute quantification of circulating tumor cell RNA enables high specificity detection of hepatocellular carcinoma (2017) (0)
ASO Visual Abstract: Neoadjuvant versus Postoperative Chemoradiotherapy Is Associated with Improved Survival in Patients with Resectable Gastric and Gastroesophageal Cancer (2021) (0)
Long-Term Outcomes and Toxicity of Anal Cancer Patients Treated Per Radiation Therapy Oncology Group 0529 (2016) (0)
Abstract 5304: RNA sequencing of circulating tumor cells implicates WNT signaling in pancreatic cancer metastasis (2012) (0)
Phase I study of geWtinib, irinotecan, 5-Xuorouracil and leucovorin in patients with metastatic colorectal cancer (2007) (0)
Severe lymphopenia predicts poorer survival in patients with rectal cancer undergoing neoadjuvant chemoradiation. (2021) (0)
Long-Term Results of a Multi-Institutional Phase II Study of Hypofractionated Proton Beam Irradiation of Unresectable Primary Liver Tumors (2022) (0)
IMPROVED OUTCOME OF PANCREATIC ADENOCARCINOMA ARISING IN INTRADUCTAL PAPILLARY MUCINOUS TUMORS IS DUE TO EARLIER STAGE AT PRESENTATION (2007) (0)
Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. CANCER (0)
Imaging , Diagnosis , Prognosis CirculatingOncometabolite 2-Hydroxyglutarate Is aPotential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma (2014) (0)
Living with Cancer: A Step-by-Step Guide for Coping Medically and Emotionally with a Serious Diagnosis (2017) (0)
Dose Escalation Radiation with IORT for Unresectable Pancreatic Cancer in the Era of FOLFIRINOX (2020) (0)
Phase I and Pharmacokinetic Study of Gimatecan Given Orally Once aWeek for 3 of 4 Weeks in Patients with Advanced SolidTumors (2008) (0)
Gender Disparities in Philanthropic Fundraising by Academic Oncologists (2020) (0)
2099 : Adjuvant Therapy for Invasive Intraductal Papillary Mucinous Neoplasms of the Pancreas (2006) (0)
Rectal Cancer NCCN Rectal Cancer Panel Members Continue (0)
The impact of positive margins on outcome among patients with gastric cancer treated with radiation. (2013) (0)
Scan? Cure? Sure! (2011) (0)
Prognostic impact of chemoradiation-related lymphopenia in patients with locally advanced pancreatic cancer. (2021) (0)
Association of Dosimetric and Treatment Related Factors with Radiation Induced Lymphopenia and Overall Survival among Patients Treated in the FOLFIRINOX Era (2018) (0)
Biomarker-Driven Therapy in the Neoadjuvant Treatment of Colorectal Liver Metastases (2012) (0)
Phase I study of S-1 administrated for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer (AUGIC) (2005) (0)
Tolerability of Dose Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally-Advanced Pancreatic Cancer (2013) (0)
Abstract A18: Angiotensin receptor blockers normalize the pancreatic ductal adenocarcinoma stroma by reprogramming carcinoma-associated fibroblasts (2019) (0)
Society of abdominal radiology disease-focused panel (DFP) on rectal and anal cancer: annual short report (2019) (0)
Abstract 956: Receptor tyrosine kinases, not KRAS, activate PI3K in KRAS mutant colorectal cancers (2011) (0)
Response prediction of neoadjuvant chemoradiation therapy in locally advanced rectal cancer using CT-based fractal dimension analysis (2021) (0)
Neoadjuvant versus Postoperative Chemoradiotherapy in Gastric Cancer (2020) (0)
Su1672 Predictors of Lymph Node Involvement in T1 Gastric Carcinoma (2013) (0)
Symptom burden and hospital length of stay among patients with curable cancer. (2017) (0)
Clinical Correlates of Portal Venous or Superior Mesenteric Vein Thrombosis Following Neoadjuvant Therapy with Dose Escalated Radiation for Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma. (2021) (0)
Mutational Profile of Gastroesophageal Cancer Compared to Gastric and Esophageal Cancers (2013) (0)
Assessment of complete pathologic response after neoadjuvant immunotherapy for MSI-H gastrointestinal cancers. (2023) (0)
Randomized trial of a symptom monitoring intervention for hospitalized patients with advanced cancer (NCT03396510). (2020) (0)
Hepatic Arterial Infusion Pump: Quo Vadis? (2022) (0)
Case records of the Massachusetts General Hospital. Case 20-2005. A 58-year-old man with locally advanced pancreatic cancer. (2005) (0)
Quality improvement interventions to reduce chemotherapy dose-modification ordering errors at a large academic medical center. (2018) (0)
Tolerability of Chemoradiation for Upper Gastrointestinal Malignancies in Patients 75 Years and Older (2008) (0)
Changes in patient-reported outcomes (PROs) and tumor markers (TMs) to predict treatment response and survival outcomes in patients with metastatic gastrointestinal (GI) cancer. (2021) (0)
A phase II study of niraparib and dostarlimab with radiation in patients with metastatic pancreatic cancer. (2022) (0)
Prognostic impact of chemoradiation-related lymphopenia in patients with gastric and gastroesophageal cancer. (2021) (0)
LAPSG Society News (2005) (0)
Addition of losartan to FOLFIRINOX and chemoradiation reduces immunosuppression-associated genes, Tregs and FOXP3+ cancer cells in locally advanced pancreatic cancer. (2023) (0)
Total Neoadjuvant Therapy versus Neoadjuvant Chemoradiotherapy in the Management of Gastric Cancer (2020) (0)
P PROGNOSIS IMPACT OF POSTOPERATIVE RADIATION IN PATIENTS WITH RADICAL ESOPHAGECTOMY AND PATHOLOGIC LYMPH NODES POSITIVE ESOPHAGEAL CANCER (2012) (0)
Local and systemic recurrence following total neoadjuvant therapy (TNT) and resection for borderline resectable and locally advanced pancreatic adenocarcinoma: Long-term follow up from two phase II studies. (2021) (0)
Abstract 2210: Activation of PI3K in Merkel cell carcinoma (2011) (0)
Basics of Chemotherapy (2017) (0)
Prognostic Impact of Chemoradiation-Related Lymphopenia in Patients with Squamous Cell Carcinoma of the Anal Canal (2020) (0)
Phase Ib study testing neoadjuvant transforming growth factor (TGF)-β antibody, NIS793, plus 5-fluorouracil, irinotecan, and oxaliplatin chemotherapy (FOLFIRINOX) in patients (pts) with borderline resectable (BR)/locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC). (2023) (0)
Cytoreductive Surgery Plus HIPEC for Metastatic Colon Cancer (2011) (0)
Abstract PO-097: Addition of losartan to FOLFIRINOX and chemoradiation reduces the expression of pro-invasive and immunosuppressive genes in locally-advanced pancreatic cancer (2021) (0)
Phase Ib Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer. (2021) (0)
Chemotherapy order review, activation, preparation, and administration redesign at a large academic cancer center. (2013) (0)
Chemoradiation-related lymphopenia and its association with survival in patients with anal cancer. (2020) (0)
Abstract A115: Use of angiotensin system inhibitors is associated with immune activation and longer survival in pancreatic ductal adenocarcinoma patients (2019) (0)
Commentary (Ryan/Clark): Management of Anal Cancer in the HIV-Positive Population (2005) (0)
Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days1, 3, and 5 Every 3 Weeks in Patientswith Advanced Solid Tumors (2005) (0)
Evaluating adherence to off-label policy at an academic outpatient cancer center and assessing reimbursement of high-cost drugs. (2013) (0)
Local Therapy for a Systemic Disease: Indications and Impact of Radiation Therapy to the Pancreatic Primary in Metastatic Pancreatic Cancer (2019) (0)
In reply [2] (2006) (0)
Sexual Function, Quality of Life (QOL), and Mood After Radiation Therapy in Patients With Anal Cancer. (2016) (0)
The role of HIPEC in patients with advanced colorectal cancer. (2020) (0)
Outcomes and Tolerability of Full Dose Chemoradiation for Locally Advanced Esophageal Cancer in Patients Age 75 or Older (2008) (0)
Justification of more expensive antiemetic use with FOLFOX at an ambulatory cancer center. (2014) (0)
The immune milieu of anal squamous cell carcinoma and implications of IDO expression on outcome. (2018) (0)
Patient-reported Acute Gastrointestinal Outcomes during Dose-painted Intensity Modulated Radiation Therapy and Concurrent Chemotherapy for Anal Cancer (2011) (0)
Clinical characteristics and treatment outcomes of patients with metastatic, MET-amplified esophagogastric cancers. (2015) (0)
Patterns of Care for Older versus Younger Patients with Pancreatic Cancer (2020) (0)
Pretreatment Tumor Size is Associated with Pathologic Complete Response to Preoperative Chemoradiation for Locally Advanced Rectal Adenocarcinoma (2011) (0)
A Phase 1b clinical trial of LDE225 (Sonidegib) in combination with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFIRINOX) in previously untreated locally advanced or metastatic pancreatic adenocarcinoma (2021) (0)
1050 – Linear Support Vector Machine Learning Model is Highly Specific for Predicting Low-Grade Intraductal Papillary Mucinous Neoplasm Lesions (2019) (0)
Abstract LB-011: Patient-derived organoids may facilitate precision medicine in pancreatic cancer: Demonstrating feasibility in the context of a multi-center clinical trial (2020) (0)
Inflammatory Signaling in Pancreatic Cancer Transfers Between a Single-cell RNA Sequencing Atlas and Co-Culture (2022) (0)
Systemic and targeted therapies for pancreatic ductal adenocarcinoma (2020) (0)
Abstract PR004: Characterizing the effects of neoadjuvant therapy in PDAC (2022) (0)
Chemotherapeutic Strategies for Resectable Colorectal Liver Metastases (2008) (0)
Code status transitions from full code to do-not-resuscitate (DNR) among hospitalized patients with advanced cancer. (2017) (0)
Use of patient-reported outcomes (PROs) to predict treatment outcomes in patients with advanced cancer. (2020) (0)
Relationship between symptom burden and hospital length of stay (LOS) in patients with incurable cancer. (2016) (0)
Circulating Tumor DNA to Predict Surgical Outcome after Neoadjuvant Chemoradiation for Borderline Resectable/Locally Advanced Pancreatic Cancer (2018) (0)
Clinical staging in pancreatic adenocarcinoma underestimates extent of disease (2019) (0)
A phase I, first-in-human study of TAK-164, an antibody–drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C (2023) (0)
Tolerance and toxicity of oxaliplatin-based chemotherapy regimens in individuals ≥ 75 years old with colorectal cancer (2008) (0)
Correction to: A phase I, first-in-human study of TAK-164, an antibody–drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C (2023) (0)
Aggressiveness of care and overall survival in young metastatic colorectal cancer patients. (2019) (0)
Pathologic assessment of tumor regression after neoadjuvant therapy for locally advanced/borderline resectable pancreatic cancer (2016) (0)
A prospective study of capecitabine (cape), oxaliplatin (ox), bevacizumab (B), and radiation therapy (RT) (CAPOX-B RT) in patients with locally advanced or R1 biliary cancers: High risk of liver failure with extended hepatectomy. (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With David Patrick Ryan?

David Patrick Ryan is affiliated with the following schools:

Autonomous University of Barcelona
University of Hong Kong
California South Bay University
Massachusetts General Hospital
Harvard University